Oncology Pharma Advances Progress on Multiple Fronts Including Advanced Attention to Connect2Trials' Commercial Development
May 09 2022 - 8:48AM
InvestorsHub NewsWire
Oncology Pharma Advances Progress on Multiple Fronts Including
Advanced Attention to Connect2Trials' Commercial
Development
San Francisco, CA -- May 9, 2022 -- InvestorsHub NewsWire
-- Oncology Pharma Inc. (OTC PINK: ONPH) - Oncology Pharma, Inc. ("The
Company") is pleased to execute its next phase with Connect2Trials,
Inc. Originally, the Company engaged with Ribera Solutions,
Inc.'s "Connect2Med" on its patient engagement platform for
clinical trials. Ribera has diligently worked on advancing
its technology and engagement with pharma and biotech companies
with the support of Oncology Pharma. During this time,
Connect2Med has advanced its technology and created a focused
standalone company under the banner Connect2Trials, Inc.
Oncology Pharma has been happy to continue to provide
financial and operational support to the new entity.
Oncology Pharma is actively working with Connect2Trials in the
development of the patient engagement portal and in connecting the
company with Clinical Research Organizations (CROs) and other
research, biotech and pharma companies that may ultimately be
clients of the company generating revenue. The Company has
committed to see the process through to commercialization which it
expects to see in the coming quarter with the adequate financing
being made available.
Connect2Trials, Inc. is currently developing a prototype to
present and demonstrate capabilities to companies including some of
the largest pharma and biotech companies in the industry. The
prototype target date is scheduled for late June of 2022 subject to
the availability of adequate financing. Connect2Trials
is in current discussions with some of the top CROs, Advocacy
Groups, and Pharma Companies for potential partnerships for pilot
deployment of its MVP (Minimum Viable Product) release scheduled
for 2nd quarter of this year.
For Pharmaceutical companies, CROs and sites running clinical
trials, Connect2Trials offers a highly engaging patient retention
platform that keeps patients motivated to complete the trial, which
is currently a challenge for many trials. The Connect2Trials does
this through community and peer to peer interactions and
incentives.
Oncology Pharma, through its investment and continuation of
financing Connect2Trials is poised to become a significant player
in the trials and patient engagement space in order to increase the
results of clinical trials utilizing technology and patient
engagement formulas to improve the retention rate, value
proposition and eventual better clinical trials in the
industry.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the "Company") is currently
engaging in research and development of therapeutics for oncology
and prides itself for having a world-class Advisory Board that
keeps the Company in the forefront of developing technologies in
cancer research, biotechnology, and healthcare.
ABOUT Ribera Solutions, LLC (Connect2Trials, inc.)
(www.riberasolutions.com / www.connect2trials.com)
Ribera Solutions (CA, USA) has developed Web based Connect2Med
platform, which has been recently assigned to Connect2Trials, Inc.,
with iOS and Android mobile Apps. Ribera's mission is to
provide solutions for solving challenging problems timely through
simple, practical and economical approaches.
FORWARD LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain
forward-looking statements that involve material risks to and
uncertainties in the Company's business that may cause actual
results to differ materially from those anticipated by the
statements made herein. Such risks and uncertainties include risks
related to licensing arrangements and joint ventures, including the
need to negotiate the definitive agreements for the relationships;
possible failure to realize anticipated benefits of business
relationships; and, costs of providing funding to these business
relationships. Other risks and uncertainties relating to the
Company include, among other things, current negative operating
cash flows and a need for additional funding to finance our
operating plan; the terms of any further financing, which may be
highly dilutive and may include onerous terms; unexpected costs and
operating deficits, and lower than expected sales and revenues;
uncertain willingness and ability of customers to adopt new
technologies and other factors that may affect further market
acceptance; adverse economic conditions; adverse results of any
legal proceedings; the volatility of our operating results and
financial condition; inability to attract or retain qualified
senior management personnel, including sales and marketing
personnel; our ability to establish and maintain the proprietary
nature of our technology through the patent process, as well as our
ability to possibly license from others patents and patent
applications necessary to develop products; the Company's ability
to implement its long range business plan for various applications
of its technology; the Company's ability to enter into agreements
with any necessary marketing and/or distribution partners and with
any strategic or joint venture partners; the impact of competition;
the obtaining and maintenance of any necessary regulatory
clearances applicable to applications of the Company's technology;
management of growth; and, other risks and uncertainties. This is
not a solicitation to buy or sell securities and does not purport
to be an analysis of the Company's financial position.
CONTACTS:
For additional Information, please contact the Oncology Pharma
at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
website: www.oncology-pharma.com
email: info@oncology-pharma.com
Oncology Pharma (CE) (USOTC:ONPH)
Historical Stock Chart
From Jul 2024 to Aug 2024
Oncology Pharma (CE) (USOTC:ONPH)
Historical Stock Chart
From Aug 2023 to Aug 2024